<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock? — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?</h2>
    <div class="badge">2025-09-15T13:53:00+00:00</div>
    <ul>
      <li>Libtayo’s performance has been good so far, as sales totaled $661.6 million in the first half of 2025, up 18% year over year.</li>
<li>Image Source: Zacks Investment Research The bottom-line estimate for 2025 has moved up $2.22 to $38.71 over the past 60 days and the same for 2026 has increased 63 cents.</li>
<li>Shares of Regeneron Pharmaceuticals (REGN) have lost 21.1% year to date against the industry’s growth of 5.2%.</li>
<li>Eylea HD sales in the United States surged 29% in the second quarter due to higher sales volumes driven by increased demand.</li>
<li>REGN currently carries a Zacks Rank #3 (Hold).</li>
<li>Today, you can download 7 Best Stocks for the Next 30 Days.</li>
<li>Roche has designed Vabysmo to block pathways involving Ang-2 and VEGF-A.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=REGN%20Loses%2021.1%25%20Year%20to%20Date%3A%20Buy%2C%20Sell%20or%20Hold%20the%20Sock%3F%0A%E2%80%A2%20Libtayo%E2%80%99s%20performance%20has%20been%20good%20so%20far%2C%20as%20sales%20totaled%20%24661.6%20million%20in%20the%20first%20half%20of%202025%2C%20up%2018%25%20year%20over%20year.%0A%E2%80%A2%20Image%20Source%3A%20Zacks%20Investment%20Research%20The%20bottom-line%20estimate%20for%202025%20has%20moved%20up%20%242.22%20to%20%2438.71%20over%20the%20past%2060%20days%20and%20the%20same%20for%202026%20has%20increased%2063%20cents.%0A%E2%80%A2%20Shares%20of%20Regeneron%20Pharmaceuticals%20%28REGN%29%20have%20lost%2021.1%25%20year%20to%20date%20against%20the%20industry%E2%80%99s%20growth%20of%205.2%25.%0A%E2%80%A2%20Eylea%20HD%20sales%20in%20the%20United%20States%20surged%2029%25%20in%20the%20second%20quarter%20due%20to%20higher%20sales%20volumes%20driven%20by%20increased%20demand.%0A%E2%80%A2%20REGN%20currently%20carries%20a%20Zacks%20Rank%20%233%20%28Hold%29.%0A%E2%80%A2%20Today%2C%20you%20can%20download%207%20Best%20Stocks%20for%20the%20Next%2030%20Days.%0A%E2%80%A2%20Roche%20has%20designed%20Vabysmo%20to%20block%20pathways%20involving%20Ang-2%20and%20VEGF-A.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fregn-loses-21-1-year-to-date-buy-sell-or-hold-the-sock%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/regn-loses-21-1-date-135300786.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>